Nanotechnology’s Latest Oncolytic Agent: Silver, Cancer & Infection Associations (Part III) By John Apsley, DC, Kent Holtorf, MD, Eric Gordon, MD, Wayne Anderson, ND, and Rashid Buttar, DO
Landmark studies over the past several decades have demonstrated that oligodynamic Ag+ (i.e., ionic colloidal silver) could play a pivotal role in overcoming cancerous processes. The authors of this white paper reviewed many of those findings and offer some dramatic case histories of cancers being cured in human test subjects.
The authors wrote, “Silver-based drugs have one core common denominator – their active ingredient is their content of “oligodynamic” silver ions (i.e., Ag+ )… Modern nanoscience is still making new discoveries regarding oligodynamic metals. Nanoscientists appear positioned to develop some of the most complicated strategies for fighting cancer. For example, they are discovering that cancer drugs must be able to easily disrupt and penetrate tumor cell membranes in situ to enable the fullest possible oncolytic effects. Picoscalar or nearpicoscalar oligodynamic Ag+ hydrosol enjoys the greatest surface presentation (i.e., ~ 6 km2 per gram Ag) for tumor cell membrane adherence and penetration, leading to greater oncolytic effects.”
After providing insights into some of the most recent clinical studies the author’s concluded, “It has long been suspected that infectious agents are associated with solid tumor cancers (a notable example is Kaposi’s Sarcoma) as well as non-tumor based cancers such as leukemia…Oligodynamic Ag+ may have the potential to play a dual role: either destroy the infectious etiological agent of the cancer, and/or destroy the pathogen loads arising within immunocompromised patients.”
